MAPT and Alzheimer disease: The value of new biomarkers demonstrates that the consideration of diverse AD pathophysiology (e.g., other than Aβ- and tau-centered aspects, such as neurodegeneration, synaptic dysfunction, neuroinflammation, lipid dysmetabolism, and disturbed protein clearance) would help to develop useful disease-tracking AD biomarkers.